logo
Share SHARE
FONT-SIZE Plus   Neg

Merck KGaA Says PETACC-8 Study Of Erbitux Shows No Benefit At Interim Analysis

Merck KGaA (MKGAY.PK) revealed results from an interim analysis of the Phase III clinical trial PETACC-81.

The study investigated the potential clinical utility of Erbitux (cetuximab) for the adjuvant treatment of stage III colon cancer after complete surgical removal of the primary tumor.

The pre-specified interim analysis of the study did not support benefit in disease free survival for patients given Erbitux plus standard chemotherapy (FOLFOX 4) compared with patients treated with FOLFOX 4 alone. Therefore this interim analysis does not support the use of Erbitux for the adjuvant treatment of stage III colon cancer in this setting.

"We are disappointed not to see an improvement in disease free survival after 3.3 years of median follow up" said Professor Julien Taïeb from the Hôpital Européen Georges Pompidou, Paris, and the PETACC-8 Principal Investigator. "Unfortunately, since the introduction of FOLFOX as standard treatment, all attempts to further improve prevention of disease recurrence have proved unsuccessful. We look forward to sharing our data at future scientific congresses."

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Grab, the Singapore-based ride hailing company and Uber's biggest Asian rival, said Monday that Chinese ride-sharing company Didi Chuxing and Japan's SoftBank Group Corp. will invest a combined $2 billion to lead Grab's new financing round. Delta Air Lines is allowing some passengers use fingerprints instead of their boarding passes. The pilot program at the Reagan Washington National Airport or DCA will allow members of Delta's SkyMiles loyalty program and enrolled in Clear, a third-party biometric screening program, to use fingerprints as proof of identity to board their plane, the company said in a statement. Oilfield services company Halliburton Co. reported Monday a profit in its second quarter, compared to a hefty loss last year, boosted mainly by strong demand in North America. In pre-market activity on the NYSE, Halliburton shares were gaining 3.9 percent.
comments powered by Disqus
Follow RTT